EMEA-003478-PIP01-23 - paediatric investigation plan

zasocitinib

Key facts

• Active substance:
  zasocitinib
• Therapeutic area:
  Skin and subcutaneous tissue disorders
• Decision number:
  P/0182/2024
• PIP number:
  EMEA-003478-PIP01-23
• Pharmaceutical form(s):
  • Film-coated tablet
  • Age appropriate oral formulation
• Condition(s) / indication(s):
  Treatment of psoriasis
• Route(s) of administration:
  Oral use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  15/05/2024
• Compliance check done:
  No

Decision

P/0182/2024: EMA decision of 15 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zasocitinib (EMEA-003478-PIP01-23)

Adopted Reference Number: EMA/224149/2024